engleski

Biomonitoring of genome integrity in human population with thyroid diseases: a pilot study

Presented results are part of three-phase-study that aims to improve cancer prevention. In the phase one of the study, the genome integrity is biomonitored using micronucleus and comet tests in patients with thyroid diseases. Thyroid cancer is one of the fastest growing types of cancer in the world. Its molecular pathogenesis and mechanisms are closely related to changes in the genome what makes it a good model for such study. The study population consisted of 24 volunteer patients (18 female: 6 male, average age 48.75 years) diagnosed with follicular adenoma (9), papillary cancer (8), goitre (6) and thyroiditis (1). The analysis of DNA damage in peripheral blood lymphocytes for this group resulted with average total number of: micronuclei (MNi) 12.43±4.14, nucleoplasmic bridges (NPBs) 4.05±3.49, and nuclear buds (NBs) 6.43±4.36 per 1000 binuclear lymphocytes. Comet assay parameters were analysed in 200 lymphocytes and the mean values were for tail intensity (TI) 3.83±2.00 and for tail moment (TM) 0.18±0.12. When compared to control population that consisted of 24 healthy volunteers (18 female: 6 male, average age 48.46 years), significantly (p<0.05) lower average total number of MNi (5.55±3.10), NPBs (0.55±0.69), NBs (2.80±1.54), TI (2.19±0.76) and TM (0.09±0.04) was observed. At the same time cytokinesis-block proliferation index (CBPI) 2.031±0.098 vs 2.067±0.082 did not differ statistically between two groups. The results of this pilot study suggest that patients with thyroid diseases have more DNA damage. In the next phases of the study the DNA damage of larger number of volunteer patients will be associated with mutant proteins from diseased thyroid tissues and with the telomere length. Overall results will provide great basis for detection of biomarkers that could be used for better risk assessment of cancer diseases and therefore for improvement of cancer prevention.

biomonitoring; thyroid cancer; micronucleus test; comet assay

nije evidentirano